APA (7th ed.) Citation

BP, E., JM, R., KL, B., E, L., F, G., A, K., . . . I, S. (2022). COVID-19 redux: Clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir. MedRxiv : the preprint server for health sciences. https://doi.org/10.1101/2022.06.16.22276392

Chicago Style (17th ed.) Citation

BP, Epling, et al. "COVID-19 Redux: Clinical, Virologic, and Immunologic Evaluation of Clinical Rebound After Nirmatrelvir/ritonavir." MedRxiv : The Preprint Server for Health Sciences 2022. https://doi.org/10.1101/2022.06.16.22276392.

MLA (9th ed.) Citation

BP, Epling, et al. "COVID-19 Redux: Clinical, Virologic, and Immunologic Evaluation of Clinical Rebound After Nirmatrelvir/ritonavir." MedRxiv : The Preprint Server for Health Sciences, 2022, https://doi.org/10.1101/2022.06.16.22276392.